Dr Nicola Antonucci

 

Dr Nicola Antonucci


MD from University of Bari, Italy in July 2000. Specialized in the same University in Psichiatry in January 2005. During the School of Specialization he was member of research of “Gruppo di Neuroscienze Psichiatriche” and worked on NeuroImaging Field using functional MRI and Spectroscopy  applied in patients affected by schizofrenia.
Since October 2006, when his daughter was diagnosed ASD, he started to work with Biomedical Treatment of ASDs using the knowledge of Autism Research Institute – San Diego (CA). He followed medical training  for several months at the “The Rimland Centre – Lynchburg (VA)” under the mentoring of Dr E. Mumper. He is still attending annual scientific meeting and training of Autism Research Institute.
He is now director of the “Biomedical Centre for Autism Research and Treatment” in Bari – Italy and working in several towns of Italy, as well as in several Countries exclusively with children affected by ASDs. In 2010, in collaboration with Dr. Dario Siniscalco, Second University of Naples, he founded a research group to study molecular and cellular changes in ASDs. This group is conducting several research trials and has already published some works on international peer-reviewed journals in the field of Autism. 

 

Abstract

With the name Autism Spectrum Disorders are described an eterogeneous cluster of “diseases” with large spectrum of neurological symptoms and  clinical abnormalities affecting different organs. This large variety of clinical manifestations presupposes a multifactorial complex origin and several aetiological factors. 

Despite this etereogenity, in more than last two years of clinical experience, the treatment with GcMAF imposed itself as one of the most important and effective clinical strategy in all the possible subsets of patients affected by Autism Spectrum Disorders.

In this presentation, data from 400 patients affected by Autism Spectrum Disorders will be shown, together with the correct procedure of administration, the management and monitoring of the treatment; the percentage of improvement and in which area it is achieved will be also shown.